Mario Cruz-Rivera

Q: What is Mario Cruz-Rivera email address?

Email Mario Cruz-Rivera at fcaaai.mariocruz-rivera@sanofi.com. This email is the most updated Mario Cruz-Rivera email found in 2026.

Q: How to contact Mario Cruz-Rivera?

To contact Mario Cruz-Rivera send an email to fcaaai.mariocruz-rivera@sanofi.com. (updated on October 29, 2024)

Global Medical Director - Medical Lead, Rx-to-OTC Switch at Sanofi | Wilmington, Delaware, United States

About Mario Cruz-Rivera

Mario Cruz-Rivera serves as the Global Medical Director and Medical Lead for Rx-to-OTC Switch at Sanofi, where he leverages over 30 years of extensive experience in clinical development to spearhead innovative strategies that facilitate the transition of prescription medications to over-the-counter availability. In his current role, Mario is pivotal in leading the medical evaluations and due diligence processes for potential Rx-to-OTC switch assets. His collaborative approach involves working closely with cross-functional teams, including Regulatory Affairs, Clinical, Commercial, Business Development, and Competitive Intelligence, ensuring that all aspects of the switch process are meticulously aligned with regulatory requirements and market needs.

Mario's expertise encompasses the comprehensive strategy, design, and execution of Consumer Label Development programs, which are critical for ensuring that consumers can safely and effectively self-select medications. His leadership in Label Comprehension and Self-Selection studies not only enhances consumer understanding but also drives successful product launches in the competitive OTC market. With a strong foundation in Good Clinical Practice (GCP) and a proven track record in regulatory submissions, Mario is adept at navigating the complexities of pharmaceutical research and drug discovery, particularly in therapeutic areas such as respiratory disease and gastroenterology.

His ability to manage high-performing, integrated clinical development teams has been instrumental in delivering Phase 1 through Phase 4 clinical development programs, resulting in successful global regulatory approvals. Mario’s commitment to excellence and innovation positions him as a key player in advancing Sanofi's mission to improve patient access to essential medications through strategic Rx-to-OTC transitions.

Mario Cruz-Rivera Work